Skip to content

BeiGene

US · ONC #538 by market cap Listed 2016
390.94 -8.76 -2.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Hong Kong Stock Market Movers | BeiGene (06160) Rises Over 3% in Early Trading; Full-Year Revenue Guidance Raised for the Third Time This Year as Innovation Pipeline Approaches Commercialization Phase
    Zhitong Finance · 2026/11/12
  • Rating change
    Major Bank Ratings | UOB Kay Hian: Raises BeiGene’s target price to HKD 300, maintains “Buy” rating
    Gelonghui Finance · 2026/11/9
  • Rating change
    A Quick Look at Today's Ratings for BeiGene(ONC.US), With a Forecast Between $435 to $477
    Market Newswire · 2026/11/7
  • Company notice
    BEONE MEDICINES: INSIDE INFORMATION - UNAUDITED RESULTS FOR THE THREE AND NINE MONTHS ENDEDSEPTEMBER 30, 2026 OFBEONE MEDICINES LTD. AND BUSINESS UPDATES
    HKEX · 2026/11/5
  • BeiGene (06160): A total of 15,400 restricted share units in the form of American Depositary Shares were granted under the 2016 Option and Incentive Plan.
    Zhitong Finance · 2026/11/12
  • Rating change
    Research Insights | CSC Financial: Maintains "Buy" rating on BeiGene as innovative pipeline approaches commercialization phase
    Gelonghui Finance · 2026/11/11
  • Rating change
    Morgan Stanley Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $476
    Market Newswire · 2026/11/13
  • Rating change
    BeiGene (06160.HK): Earnings Beat Expectations as High-Speed Growth Continues
    Guojin Securities · 2026/11/5
  • BeiGene (06160) plans to invest USD 19.5 million in Bravera's Series A financing round.
    Zhitong Finance · 2026/11/16
  • Company notice
    BEONE MEDICINES: INSIDE INFORMATION - UNAUDITED RESULTS FOR THE THREE MONTHS ENDEDDECEMBER 31, 2025 AND AUDITED RESULTS FOR THE YEARENDED DECEMBER 31, 2025 OFBEONE MEDICINES LTD. AND BUSINESS UPDATES
    HKEX · 2026/2/26
  • BeiGene Responds to Rumors of County-Level Team Dissolution: Does Not Mean Exit from Broad Market
    Latest · 2026/11/20
  • Company notice
    BEONE MEDICINES: INSIDE INFORMATION -UNAUDITED RESULTS FOR THE THREE AND NINE MONTHSENDED SEPTEMBER 30, 2025 OFBEONE MEDICINES LTD. AND BUSINESS UPDATES
    HKEX · 2025/11/6
  • Company notice
    BEONE MEDICINES: INSIDE INFORMATION - UNAUDITED RESULTS FOR THE THREE AND SIX MONTHSENDED JUNE 30, 2026 OFBEONE MEDICINES LTD. AND BUSINESS UPDATES
    HKEX · 2026/8/5
  • Company notice
    BEONE MEDICINES: INSIDE INFORMATION - UNAUDITED RESULTS FOR THE THREE MONTHS ENDEDMARCH 31, 2026 OFBEONE MEDICINES LTD. AND BUSINESS UPDATES
    HKEX · 2026/5/6
  • Rating change
    RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $459
    Market Newswire · 2026/10/28
  • Rating change
    Barclays Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $446
    Market Newswire · 2026/11/6
  • Rating change
    Daiwa: Raises BeiGene (06160) target price to HK$286; third-quarter results again beat expectations
    Zhitong Finance · 2026/11/10
  • Rating change
    Major Bank Ratings | Daiwa: BeiGene's Q3 Results Beat Expectations and Full-Year Guidance Raised; Target Price Increased to USD 476
    Gelonghui Finance · 2026/11/10
  • J.P. Morgan Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $460
    Market Newswire · 2026/11/19
  • Rating change
    BeiGene (06160.HK): Q3 2026 Results Exceed Expectations; Product Gross Margin Remains High
    Chun Yee Securities (Hong Kong) · 2026/11/6
  • [Blue Chips] BeiGene (06160.HK) reports a 285% year-on-year increase in net profit to USD 849 million for the first three quarters, raising full-year guidance
    AASTOCKS · 2026/11/6
  • Rating change
    Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $420
    Market Newswire · 2026/10/9
  • Rating change
    BeOne Medicines Ltd (6160) Receives a Buy From UBS
    TipRanks · 2026/10/21
  • Rating change
    RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $459
    Market Newswire · 2026/10/8
  • Rating change
    Truist Financial Maintains BeiGene(ONC.US) With Buy Rating
    Market Newswire · 2026/10/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

BeiGene discussion 0 comments

Add a comment